Molloy 2002.

Methods	Cross‐over trial of single dose secretin versus placebo
Participants	Inclusion criteria: 2–15 years of age met the criteria for autism as outlined in the DSM‐IV following multidisciplinary evaluation, "Children not evaluated at our center were accepted into the sampling frame if documentation of diagnosis by a multidisciplinary team was sufficient as determined by a developmental pediatrician (SS)." Exclusion criteria: "had known chromosomal or other genetic disorders, a structural abnormality on neuroimaging, had previously received secretin, had acute or chronic pancreatic disease or a medical condition that might make participation in the study unsafe". Location/setting: Children's Hospital Medical Centre, Cincinnati, Ohio, USA Sample size: 60 Number analysed: secretin first: 19, placebo first: 23 Number of withdrawals/dropouts: 18 dropped out from original 60, although reasons for only 1 participant provided (from placebo/secretin group) ‐ they did not return for the final assessment. Gender: 37/42 analysed were male participants Mean age: 6.8 years IQ: not reported Baseline ABC‐I or other BoC: not reported Concurrent medications: not reported History of previous medications: not reported
Interventions	Intervention (single dose secretin): a single dose of 2 IU/kg of intravenous synthetic human secretin was given at the first visit of the phase. Comparator (single dose placebo): a single dose of 2 IU/kg of placebo was given at first visit of the phase.
Outcomes	Primary outcomes: parent‐rated ABC (not reported) (Aman 1985) AEs (not reported) Secondary outcomes: none reported Timing of outcome assessments: baseline, and weeks 1, 3, 6, 9 and 12
Notes	Study start date: not reported Study end date: not reported Source of funding: "supported by Grant #4 T73 MC 00032‐10 awarded by the Maternal and Child Health Bureau, Health Resources and Service Administration, DHHS and by Grant #M01 RR‐08084, NIH. The human synthetic secretin used in the study was supplied by ChiRoClin (Silver Spring, MD) free of charge". Conflicts of interest: none declared Comment: author was contacted for information but no reply